Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination

Molecular Cancer Therapeutics
Pierre MordantEric Deutsch

Abstract

Activation of phosphatidylinositol-3-kinase (PI3K)-AKT and Kirsten rat sarcoma viral oncogene homologue (KRAS) can induce cellular immortalization, proliferation, and resistance to anticancer therapeutics such as epidermal growth factor receptor inhibitors or chemotherapy. This study assessed the consequences of inhibiting these two pathways in tumor cells with activation of KRAS, PI3K-AKT, or both. We investigated whether the combination of a novel RAF/vascular endothelial growth factor receptor inhibitor, RAF265, with a mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), could lead to enhanced antitumoral effects in vitro and in vivo. To address this question, we used cell lines with different status regarding KRAS, PIK3CA, and BRAF mutations, using immunoblotting to evaluate the inhibitors, and MTT and clonogenic assays for effects on cell viability and proliferation. Subcutaneous xenografts were used to assess the activity of the combination in vivo. RAD001 inhibited mTOR downstream signaling in all cell lines, whereas RAF265 inhibited RAF downstream signaling only in BRAF mutant cells. In vitro, addition of RAF265 to RAD001 led to decreased AKT, S6, and Eukaryotic translation initiation factor 4E binding p...Continue Reading

References

Apr 30, 1996·Proceedings of the National Academy of Sciences of the United States of America·S R von ManteuffelG Thomas
Nov 27, 1999·Science·S Zimmermann, K Moelling
Jun 12, 2003·Proceedings of the National Academy of Sciences of the United States of America·Alexis A BorisyCurtis T Keith
Sep 3, 2004·Proceedings of the National Academy of Sciences of the United States of America·Philippe P RouxJohn Blenis
Jan 25, 2005·Molecular Cell·Michele K DoughertyDeborah K Morrison
Dec 17, 2005·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Roy Blum, Yoel Kloog
Mar 10, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A ItalianoF Pedeutour
Apr 19, 2006·Cancer Research·Astrid LièvrePierre Laurent-Puig
Aug 3, 2006·Nature Reviews. Drug Discovery·Sandrine FaivreEric Raymond
Mar 27, 2007·Nature Reviews. Cancer·Suzanne SchubbertGideon Bollag
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bruce E JohnsonPasi A Jänne
Aug 19, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C PisanoF Zunino
Mar 5, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rafael G AmadoDavid D Chang
Mar 12, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anne O'DonnellIan Judson
Jul 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chang-Qi ZhuUNKNOWN National Cancer Institute of Canada Clinical Trials Group Study BR.21
Sep 2, 2008·Cancer Research·Hiromasa YamamotoAdi F Gazdar
Sep 18, 2008·Cancer Investigation·Nandita SaxenaRajendra Prasad Tripathi
Oct 24, 2008·The New England Journal of Medicine·Christos S KarapetisJohn R Zalcberg
Sep 10, 2009·Journal of the National Cancer Institute·Salvatore SienaAlberto Bardelli

❮ Previous
Next ❯

Citations

May 4, 2012·Archives of Pharmacal Research·Do-Hee Kim, Taebo Sim
Aug 3, 2012·Cell Reports·Lorenzo GalluzziGuido Kroemer
Dec 24, 2010·Pigment Cell & Melanoma Research·Marie C ZipserKeith S Hoek
Jan 26, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Osamu TakahashiMichael S O'Reilly
Nov 7, 2014·Cancer Chemotherapy and Pharmacology·Caroline I PiatekAgustin A Garcia
Jan 14, 2012·Expert Opinion on Therapeutic Targets·Libero SantarpiaAdel K El-Naggar
May 7, 2013·Expert Opinion on Investigational Drugs·Samra TurajlicJames Larkin
Jun 24, 2010·Expert Opinion on Investigational Drugs·Sébastien AlbertEric Raymond
Sep 18, 2012·European Journal of Medicinal Chemistry·Vikas VermaSundeep Jaglan
Oct 11, 2011·Bioscience Reports·Rolando Pérez-Lorenzo, Bin Zheng
Dec 19, 2013·Journal of Medicinal Chemistry·Thibault SauratSylvain Routier
Aug 3, 2019·Expert Opinion on Therapeutic Patents·Ruo-Jun ManHai-Liang Zhu
Aug 13, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ning JinDouglas W Ball
Dec 5, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Makoto EndoYoshinao Oda
May 17, 2021·Seminars in Cancer Biology·Rahim UllahLixin Wan
Jun 27, 2018·Chemico-biological Interactions·Elaine Maria de Souza-FagundesAdilson David da Silva

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.